#France #ESG #Strasbourg #EndoZip #Nitinotes

Nitinotes Expands Its Reach in Europe with EndoZip™ System

Nitinotes Ltd., an innovator in medical technology, recently announced the successful completion of its first commercial EndoZip™ procedures in France, marking a significant moment in the expansion of its automated suturing system for Endoscopic Sleeve Gastroplasty (ESG). These groundbreaking cases were conducted at the renowned Institute of Image-Guided Surgery in Strasbourg under the expert guidance of Prof. Silvana Perretta, a distinguished leader in foregut surgery and advanced gastrointestinal endoscopy.

This accomplishment not only signifies Nitinotes' commitment to expanding its European presence but also highlights the growing acceptance and interest in ESG technology among a broad spectrum of healthcare professionals, including both endoscopists and bariatric surgeons. Prof. Perretta's leadership was instrumental in these procedures, reflecting the increasing demand for minimally invasive solutions in obesity treatment.

Historically, the adoption of Endoscopic Sleeve Gastroplasty has been limited, primarily due to the technical complexities associated with traditional endoscopic suturing systems. However, the introduction of the EndoZip™ system is set to change this landscape. By automating key suturing steps, EndoZip aims to reduce the technical challenges faced by practitioners, thus broadening access to this effective weight loss procedure.

According to Prof. Perretta, “Obesity is one of the most pressing healthcare issues globally, and it is essential to enhance access to minimally invasive treatments. Technologies that simplify procedural execution can significantly influence the adoption of ESG across various medical specialties.” This sentiment echoes the growing acknowledgment of the importance of innovative solutions in addressing public health challenges.

Lloyd Diamond, CEO of Nitinotes, emphasized that the company's mission is to leverage automation to unlock the full potential of ESG. “The first cases in France under Prof. Perretta’s supervisory guidance not only indicate strong interest from advanced endoscopists but also suggest a positive reception from leading bariatric and foregut surgeons. This technology could indeed broaden the scope of ESG to a wider group of physicians, thereby enhancing treatment availability.”

The EndoZip™ system is designed as an automated endoluminal suturing technology intended to simplify tissue approximation during endoscopic procedures aimed at obesity treatment. Its aim is to provide a more standardized approach to ESG, enhancing the proficiency of healthcare providers and improving patient outcomes.

The successful implementation of EndoZip™ in France is part of a broader strategy that includes prior cases carried out in Italy and Spain, showcasing the ongoing momentum and acceptance of this technology within the European healthcare landscape following the CE Mark approval. Currently, EndoZip has been marked for use across Europe, but it remains limited to investigational status in the United States, highlighting its emergent place in global medical device markets.

In conclusion, Nitinotes is not just developing a product; it is paving the way for a shift in how obesity treatments are approached globally. As the healthcare sector continues to confront complex challenges related to obesity, innovations like EndoZip™ signify the potential for enhanced treatment modalities and improved patient care. For more information about Nitinotes and its products, interested parties can visit their official website at nitinotesurgical.com.

This expansion in France stands as a testimony to the evolving landscape of medical innovation, where automation and minimally invasive techniques are becoming increasingly vital in surgical procedures, thereby setting the stage for better health outcomes for patients in need of weight loss solutions.